ATX2 Polyclonal Antibody, HRP Conjugated
Product Specifications
Background
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ATX2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. ATX2 is caused by expansion of a CAG repeat in the coding region of ATX2. Longer expansions result in earlier onset of the disease. There are four named isoforms.
Synonyms
ATX2; SCA2; ASL13; TNRC13; Ataxin-2; Spinocerebellar ataxia type 2 protein; Trinucleotide repeat-containing gene 13 protein; ATXN2
Gene ID
6311
Swiss Prot
Q99700
Cellular Locus
Cytoplasm
Host
Rabbit
Cross Reactivity
Mouse
Immunogen
775-856/1313
Target
ATX2
Clonality
Polyclonal
Isotype
IgG
Conjugation
HRP
Source
KLH conjugated synthetic peptide derived from human ATX2
Applications
WB, ELISA, IHC-P, IHC-F
Purification
Purified by Protein A.
Concentration
1µg/µl
Dilution
WB (1:300-5000), ELISA (1:500-1000), IHC-P (1:200-400), IHC-F (1:100-500)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
6311
Predicted Cross Reactivity
Human, Rat, Dog, Cow, Pig, Horse, Chicken
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
